Evaluation of a Collagen Type II-Targeted Peptide-Drug Conjugate for Rheumatoid Arthritis Treatment
Tuesday, July 15, 2025
11:27 AM – 11:38 AM EDT
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing joint inflammation and pain, with current treatments like corticosteroids and DMARDs limited by poor drug retention and systemic toxicity due to rapid clearance1. Targeted drug delivery systems utilizing ligands for localized release address these issues. Collagen type II, predominantly in hyaline cartilage, offers a promising target for RA therapy. This study focuses on developing a peptide-drug conjugate targeting collagen type II, aiming to improve therapeutic efficacy while reducing off-target effects and systemic toxicity.
Learning Objectives:
At the completion of this activity, participants will know
Understand the challenges of standard RA therapies and the role of targeted drug delivery systems.
Explore the potential of collagen type II as a target for systemic drug delivery in RA treatment.
Gain insights in synthesis, characterization, and evaluation of PDC for better therapeutic outcomes.
